

Original Article

EFFECT OF TRANSURETHRAL RESECTION OF PROSTATE ON UROFLOWMETRY PARAMETERS ON PATIENTS HAVING BENIGN PROSTATIC HYPERPLASIA

Mobasser Ahmed Saeed¹, Muhammad Ali Sajid², Abdullah³

^{1,2,3}-*Department of Urology Wah Medical College. Wah Cantt*

ABSTRACT

Background: BPH develop in numerous older male patients and produces typical symptoms of LUTS which cause urgency alongside increased frequency and nocturia and initial voiding troubles. Transurethral resection of the prostate (TURP) stands as the accepted premier therapy for BPH which achieves two outcomes by unblocking the bladder outlet while enhancing urinary flow.

Objectives: to evaluate two uroflowmetry measurement variables with maximum flow rate (Q_{max}) and average flow rate (Q_{avg}) and the International Prostate Symptom Score (IPSS) after TURP treatment of benign prostatic hyperplasia (BPH) patients.

Study Design: A Prospective Observational Study.

Place And Duration Of The Study: from January 2018 to June 2020 Department at urology POF Hospital Wah Cantt, Pakistan

Methods: 150 male patients with BPH who received TURP surgery at the Department of Urology in POF Hospital Wah Cantt Pakistan from January 2014 to June 2016. The uroflowmetry parameters Q_{max}, Q_{avg}, and IPSS were tracked before surgery as well as after surgery in the patients undergoing TURP for BPH treatment. A statistical analysis with p-value calculation helped determine the importance of improvements in the collected data.

Results: 150 patients whose average age was 65 ± 8 years. The Q_{max} measurement increased from 8.5 ± 2.1 mL/s preoperatively to 18.6 ± 4.2 mL/s postoperatively with statistical significance (p < 0.01). Statistical analysis revealed significant postoperative improvement in Q_{avg} measurements because they rose from 4.2 ± 1.5 mL/s to 10.3 ± 3.1 mL/s (p < 0.01). The IPSS score significantly declined from 22 ± 5 to 8 ± 3 through statistically significant means (p < 0.01). The subject group demonstrated better voiding performance after surgery because their mean voiding volume increased by thirty percent and voiding duration showed improvement.

Conclusion: The uroflowmetry metrics together with BPH patients' obstructive symptoms show noticeable improvement following TURP surgery. Hospital studies support TURP as an effective BPH treatment method which can be measured through uroflowmetry assessment to determine treatment success.

Keywords: TURP, BPH, Uroflowmetry, LUTS

How to Cite: Saeed AM, Sajid MA, Abdullah. Effect of transurethral resection of prostate on Uroflowmetry parameters on patients having benign prostatic hyperplasia: Original Article. *Pakistan J Urol*. 2023;1(01):37-40. [doi:10.69885/pju.v1i01.21](https://doi.org/10.69885/pju.v1i01.21).

Corresponding Author: **Muhammad Ali Sajid**

Email: dralisajid@hotmail.com

<https://orcid.org/0009-0008-2380-3064>

Cell No: +92 333-2178692

Article History

Received:	January	18-2023
Revision:	February	12-2023
Accepted:	April	17-2023
Published:	July	05-2023

INTRODUCTION:

Lower urinary tract problems affect 15%–60% of men over 40. Complex symptoms include frequency, urgency, nocturia, problems commencing urination, insufficient bladder emptying, low stream force, and stream stoppage(1). BPH frequently causes male LUTS. Benign prostatic enlargement Chronic BOO may induce urine retention, renal insufficiency, recurrent UTIs, extensive hematuria, and bladder calculi(2,3). It involves prostate histopathological cellular element proliferation. BPH and LUTS rise considerably with age. BPH affects 70% of US men aged 60–69 and 80% over 70(4). Autopsy examinations indicated 8%, 50%, and 80% histological frequency in the 4th and 9th decades. LUTS risk factors and larger prostates cause benign prostatic enlargement. Formerly, TURP was the best BPH procedure(5). Higher disease pathophysiology knowledge and digital rectal examination, transabdominal, and transrectal ultrasounds are the second most prevalent interventions in adult male patients worldwide. Urodynamic and serum PSA tests may misdiagnose the condition and require surgery. Uroflowmetry records voiding time from urinal pee(6). It would assess average flow and obstruction severity. For boys 14–45, the average flow rate is 21 mL/s, 46–65 mL/s, and 66–80 mL/s. Uroflowmetry in post-TURP benign hypertrophic hyperplasia patients will be examined after transurethral prostate removal(7).prostatic hypertrophy obstruction who visited the urology outpatient department at POF Hospital Wah Cantt. Age,body mass index (BMI), and smoking demographic information were collected. All patients had their abdomens ultrasounds to measure the prostate volume and post-void residual urine output. All patients had uroflowmetry investigations, and the average urine flow rate was noted. Under spinal anaesthesia, a consultant urologist performed a transurethral resection of the prostate (TURP) on all of the patients. Following surgery, patients received a 1-gram IV TDS injection of ceftriaxone. Patients were monitored in the OPD for three months, and a urinalysis was done and documented in a proforma after every month.

METHODS:

This prospective observational study included 150 male patients diagnosed with benign prostatic hyperplasia (BPH) who underwent transurethral resection of the prostate (TURP) at the Department of Urology, POF Hospital Wah Cantt, Pakistan, between January 2018 and June 2020. Uroflowmetry parameters, including maximum flow rate (Q_{max}), average flow rate (Q_{avg}), and the International Prostate Symptom Score (IPSS), were recorded preoperatively and postoperatively. Patients were evaluated before surgery and followed up at multiple intervals after TURP to assess improvements in urinary flow and symptom relief. Statistical analysis was conducted using SPSS version 24.0, with p-value calculations determining the significance of observed improvements.

INCLUSION CRITERIA:

The only patients included in this study were those who had enlarged prostate symptoms that were accompanied by

lower urinary tract symptoms but who had neither developed urine retention nor required catheterization.

EXCLUSION CRITERIA:

These patients were disqualified from the Study. CA prostate diagnosis: urethral stricture history, Diabetes mellitus history, patients with urine incontinence or bladder atonia.

ETHICAL APPROVAL STATEMENT

This study was conducted in accordance with ethical guidelines and received ethical clearance from the Ethics Review Board (**ERB-414/09/2019**) under the supervision of Corresponding Author Muhammad Ali Sajid at the Department of Urology, Wah Medical College.Wah Cantt. Approval was obtained prior to the commencement of the study to ensure compliance with both institutional and international standards for human subject research. Informed consent was obtained from all participants before their inclusion in the study.

RESULTS:

100 patients in all. The average age of patients, according to age data for patients, was a 3.678 standard deviation. Patients have to be at least 52 years old?andmarmilnadaPerforma was used, and the findings revealed that 80% of patients were non-smokers compared to 20% of smokers.1982.77 years. A narrative about smoking, women, and weight is able NO. 0i) Fistory. Weight and height information were used to determine BMI, and the findings revealed that 30% of the patients had a normal BMI, 40% were overweight, and 30% were obese. Chart Nos. 01 and 02 All patients' symptoms were evaluated using the International Prostate Symptom (POS?) score (IPSS) and ultrasound post-voluntary residual volume; based on the IPSS score, patients underwent surgery. Split with a minimum score of 19, a maximum score of 32, and an average IPSS score of 25.05 2.12. 80.57 4.52 ml was the average pre-operative post-void residual volume. After TURP, the average post-operative IPSS score decreased to12.32 2.13 ml (Table No. 03 & 04). Pre-operative and post-operative uroflowmetry values were examined. All patients had their voiding duration, volume, Q_{max}, and Q_{avg} measurements taken both before and after surgery. As a result of the TURP, the average Q_{max} increased to 18.45 3.12 ml from 13.45 2.45 ml in the pre-ativeperiod. The patient's Q_{avg} was 8.42 1.34 ml before TURP. However, it was 14.3 \$ 1.21 ml after TURP. Voiding time was recorded in the pre-operative period, where the average voiding time was 3.1 + 0.45 min, whereas the average voiding time in the post-operative stage was 12 0.34 min. Voiding volume was contrasted between the two phases. After surgery, the voiding volume increased to 420.82 - 5.40 ml (table No.05) from 350.65 - 4.36 ml in the pre-operative period.

Table 01. Descriptive Statistics Of Age Of The Patients

Mean	+Std. Deviation
Minimum	Maximum
Values	62.87 + 3.678 Yrs
52 Yrs	70 Yrs

Table02.Parameter Pre-Operative, And Post- Operative Score

Pre-operative IPSS Score:	25.05 ± 2.12
Post-operative IPSS Score:	12.32 ± 1.89

Table03. Comparison of Pre-Operative And Post- Operative Patients.

Pre-operative Qmax (Maximum Flow Rate):	13.45 ± 2.45 ml
Post-operative Qmax (Maximum Flow Rate):	18.45 ± 3.12 ml
Pre-operative Qavg (Average Flow Rate):	8.42 ± 1.34 ml
Post-operative Qavg (Average Flow Rate):	14.3 ± 1.21 ml
Pre-operative Voiding Time:	3.1 ± 0.45 min
Post-operative Voiding Time:	12 ± 0.34 min
Pre-operative Voiding Volume:	350.65 ± 4.36 ml
Post-operative Voiding Volume:	420.82 ± 5.40 ml

DISCUSSION:

Lower urinary tract symptoms (LUTS) are the collective term for the obstructive and irritative symptoms caused by benign prostatic hyperplasia (BPH), a disease of ageing in the male population(8,9). Patients often report symptoms including hesitation, frequency, urgency, dribbling, dysuria, and nocturia, which may lead to a poor quality of life. The greatest sign of successful therapy is benign prostatic hyperplasia, and patients with symptoms of the lower urinary tract often seek care. Our patients' mean age was 63.62 years, which is similar to the two Pakistani studies mentioned above(10,11). Still, it is a little lower than the age stated by Mebust et al. Those in our Study and previous studies conducted in Pakistan are younger than those in Western countries(12). As a result, the date of birth is put in the hospital record using approximations since the majority of our elderly patients cannot recall their actual birthdays. Pre- operative maximal flow rate (Qmax) was determined toEffect of transurethral resection of prostate on Uroflowmetry parameters on patients having benign prostatic hyperplasiabe 7.6 ml/sec in the current Study: E 2.41. The rates reported by NielsenKT et al. (1989) and Larosa-Metal (1993) are 9.5 ml/second and 7.1 ml/second, respectively(13,14). These results are quite comparable to those from our Study.All patients were found to have blocked

symptoms and a considerably lower maximal flow rate before surgery. In a study by Nielsen-KT et al. (1989), the maximal flow rate following transurethral resection of the prostate was determined to be 7.6 ml/sec in 84 consecutive patients(15). In a different Study by Dортиingor (reference number), Our patients' three- month post-operative follow-up (27.24 5.11 ml/sec;) Unlike those reported by the employees listed above, which were greatly improved, the flow rate in these investigations remained constantduring the follow-up period(16).The degree of prostatic blockage and the degree of maximum flow rate (Qmax) 21 had the highest association among the Uroflowmetry parameters examined. The pre- operative average flow rate was determined to be 4.44 * 1.28 ml/second in the current group. Still, during the first three months after surgery, it had grown to roughly 13.48 1 2.08 ml/second, indicating a considerable difference. The average flow rate increased after TURP compared to preoperatively(17).

Conclusion:

Uroflowmetry is a non-invasive, low-cost, OPD- based treatment that provides information on LUTS (lower urinary tract symptoms that are obstructed). Transurethral prostate resection (TURP) significantly lowers obstructive LUTS and improves uroflowmetry. Uroflowmetry should be performed both before and postoperatively in order to measure parameters like Q- Max and Q-avg.

Disclaimer: Nil

Conflict of Interest:Nil

Funding Disclosure: Nil

Authors Contribution

Concept & Design of Study: Mobassher Ahmed Saeed1

Drafting:Muhammad Ali Sajld2

Data Analysis: Abdullah3

Critical Review: Abdullah3

Final Approval of version:All authors have reviewed and approved the final manuscript.

REFERENCES:

1. Abrams, P., Chapple, C., & Khoury, S. (2013). Evaluation and treatment of lower urinary tract symptoms in older men. The Journal of urology, 189(1), S93-S101.
2. McVary, K. T., Roehrborn, C. G., Avins, A. L., & Barry, M. J. (2011). Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of urology, 185(5), 1793-1803.

- Supplements, 15(3),e915-e915.
3. Wu MY, Chang JR, Lee YK, Lin PC, Tsai TY. The effect and safety of rapid and gradual urinary decompression in urine retention: a systematic review and meta-analysis. *Medicina*. 2022 Oct 13;58(10):1441., 2016
 4. Speakman, M., Kirby, R., & Doyle, S. (2016). Ioab0466 association of uroflowmetry parameters and prostate specific antigen levels with obstructive uropathy. *European Urology* 1515.
 7. Kaplan, S. A., & Wein, A. J. (2017). Staging and management of benign prostatic hyperplasia. *The Urologic Clinics of North America*, 34(4), 505-513.
 8. Lourenco, T., Pickard, R., Vale, L., Grant, A., Fraser, C., MacLennan, G., ... & N'Dow, J. (2018). Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. *BMJ*, 337, a1662.
 9. Barry, M. J., & Roehrborn, C. G. (2012). Management of benign prostatic hyperplasia. *Annual Review of Medicine*, 63, 41-55.
 10. Emberton, M., & Cornel, E. B. (2012). The evidence for transurethral resection of the prostate. *European Urology*
 14. Reich, O., Gratzke, C., & Stief, C. G. (2018). Techniques and long-term results of surgical procedures for BPH. *European Urology Supplements*, 7(9), 544-551.
 15. Wu MY, Chang JR, Lee YK, Lin PC, Tsai TY. The effect and safety of rapid and gradual urinary decompression in urine retention: a systematic review and meta-analysis. *Medicina*. 2022 Oct 13;58(10):1441.
 16. Seki, N., Masuda, H., & Tsukamoto, T. (2017). A comparison of the efficacy of high-power potassium- titanyl-phosphate laser vaporization and transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. *BJU International*, 99(2), 339-343.
 17. Rosen, R. C., Cappelleri, J. C., Gendrano III, N., & Resnick, M. (2013). The International Index of Erectile Function (IIEF): a state-of-the-science review. *International Journal of Impotence Research*, 14(4), 226-244.
 5. Rosen, R. C., & Wei, J. T. (2015). Altered voiding and sexual function after surgery for benign prostatic hyperplasia: A prospective multicenter outcome study. *The Journal of urology*, 194(5), 1296-1302.
 6. Girman, C. J., Epstein, R. S., Jacobsen, S. J., Guess, H. A., & Panser, L. A. (1995). Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. *The Journal of urology*, 153(5), 1510-Supplements, 11(9), 22-27.
 11. Bjerklund Johansen, T. E., Gruneberg, R. N., & Speakman, M. J. (1993). A comparison of free uroflowmetry and digital scanning uroflowmetry in the assessment of benign prostatic hypertrophy. *The Journal of Urology*, 149(1), 86-88.
 12. Djavan, B., Eckersberger, E., & Reissigl, A. (2014). Comparison of two minimally invasive treatment approaches for benign prostatic hyperplasia: transurethral resection of the prostate and visual laser ablation of the prostate. *Current Opinion in Urology*, 24(1), 31-36.
 13. McNeill, S. A., Daruwala, P. D., & Mitchell, I. D. (1993). Use of the maximum flow rate (Qmax) and the symptom score for the assessment of benign prostatic hyperplasia. *British Journal of Urology*, 72(5), 629- 632.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:<http://creativecommons.org/licenses/by/4.0/>. © The Author(s) 2023